Advertisement
Screener

uniQure N.V. (QURE) Graph

QURE Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-03-31: Revenue $3.56M; Revenue including tax (m); Cost of revenue $219.00K; Research and development $29.18M.
  • 2025-12-31: Revenue (m); Revenue including tax $5.57M*; Cost of revenue $435.00K*; Research and development $34.78M*.
  • 2025-09-30: Revenue (m); Revenue including tax $3.70M; Cost of revenue $398.00K; Research and development $34.37M.
  • 2025-06-30: Revenue (m); Revenue including tax $5.26M; Cost of revenue $656.00K; Research and development $35.38M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

QURE revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$5.84MCost of revenue$350.00KOperating income-$52.20MOther income, net-$15.97MResearch & development$33.96MSelling, general& administrative$17.37MPre-tax income-$79.22MIncome tax$1.84MNet income-$81.06M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-03-31$3.56M(m)$219.00K$29.18M$20.07M(m)$488.00K-$53.53M
2025-12-31(m)$5.57M*$435.00K*$34.78M*$21.61M*(m)-$3.92M*-$37.12M*
2025-09-30(m)$3.70M$398.00K$34.37M$19.44M(m)$8.63M-$80.53M
2025-06-30(m)$5.26M$656.00K$35.38M$13.50M(m)$425.00K-$37.72M
2025-03-31$1.57M$1.57M$197.00K$36.14M$10.91M(m)$496.00K-$43.64M
2024-09-30(m)$2.29M$264.00K$30.59M$11.57M(m)-$31.00K-$44.38M
2024-06-30(m)$11.13M$234.00K$33.66M$15.77M(m)$948.00K-$56.30M
2024-03-31(m)$8.48M$150.00K$40.69M$13.94M(m)$656.00K(m)
2023-09-30(m)$1.41M(m)$65.40M$18.07M(m)-$69.00K(m)
2023-06-30(m)$2.42M(m)$46.04M$21.18M(m)$163.00K(m)
2023-03-31(m)$5.33M(m)$60.81M$17.85M(m)-$1.21M(m)
2022-09-30(m)$1.45M(m)$48.07M$13.32M(m)-$329.00K(m)
2022-06-30(m)$497.00K(m)$46.19M$12.49M(m)-$318.00K(m)
2022-03-31(m)$1.79M(m)$45.00M$10.99M(m)-$616.00K(m)
2021-09-30(m)$1.99M(m)$36.43M$12.02M(m)$89.00K(m)
2021-06-30(m)$463.87M$23.18M$32.75M$17.30M(m)$3.26M(m)
2021-03-31(m)$454.00K(m)$32.66M$12.38M(m)$213.00K(m)
2020-09-30(m)$1.79M(m)$36.30M$10.79M(m)$0.00(m)
2020-06-30(m)$1.53M(m)$28.40M$11.51M(m)$0.00(m)
2020-03-31(m)$104.00K(m)$26.01M$9.07M(m)(m)(m)
2019-09-30(m)$1.05M(m)$23.55M$8.93M(m)(m)(m)
2019-06-30(m)$2.47M(m)$24.15M$7.87M(m)(m)(m)
2019-03-31(m)$1.14M(m)$20.54M$8.07M$28.60M(m)(m)
2018-12-31(m)(m)(m)(m)(m)$25.93M*(m)(m)
2018-09-30$3.15M$3.15M(m)$20.54M$5.90M$26.44M-$32.00K(m)
2018-06-30$3.05M$3.05M(m)$18.49M$5.90M$24.39M$361.00K(m)
2018-03-31$3.48M$3.48M(m)$17.06M$6.30M$23.36M-$92.00K(m)
2017-09-30$2.26M$2.26M(m)$20.10M$5.58M$25.69M-$278.00K(m)
2017-06-30$4.94M$4.94M(m)$16.87M$5.41M$22.28M(m)(m)
2017-03-31$3.32M(m)(m)$16.99M$6.36M$23.35M(m)(m)
2016-09-30$7.22M(m)(m)$16.60M$5.11M$21.72M$177.00K(m)
2016-06-30$4.45M(m)(m)$19.22M$7.83M$27.05M-$333.00K(m)
2016-03-31$4.29M(m)(m)$16.71M$7.30M$24.00M$557.00K(m)

Revenue and expense 6 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-06-30(m)$6.83M$853.00K$71.52M$24.41M(m)$921.00K-$81.36M
2024-06-30(m)$19.61M$384.00K$74.35M$29.70M(m)$1.60M-$121.92M
2023-06-30(m)$7.75M(m)$106.84M$39.03M(m)-$1.04M(m)
2022-06-30(m)$2.29M(m)$91.19M$23.48M(m)-$934.00K(m)
2021-06-30(m)$464.32M$23.18M$64.78M$30.30M(m)$3.47M(m)
2020-06-30(m)$1.64M(m)$54.41M$20.58M(m)$0.00(m)
2019-06-30(m)$3.61M(m)$44.69M$15.94M(m)(m)(m)
2018-06-30$6.53M$6.53M(m)$35.55M$12.20M$47.75M$269.00K(m)
2017-06-30$8.26M$8.26M(m)$33.86M$11.77M$45.63M(m)(m)
2016-06-30$8.75M(m)(m)$35.93M$15.13M$51.06M$224.00K(m)

Revenue and expense 9 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30(m)$10.53M$1.25M$105.89M$43.85M(m)$9.55M-$161.88M
2024-09-30(m)$21.90M$648.00K$104.94M$41.28M(m)$1.57M-$166.29M
2023-09-30(m)$9.15M(m)$172.25M$57.10M(m)-$1.11M(m)
2022-09-30(m)$3.74M(m)$139.26M$36.80M(m)-$1.26M(m)
2021-09-30(m)$466.31M$23.18M$101.21M$42.32M(m)$3.56M(m)
2020-09-30(m)$3.43M(m)$90.72M$31.37M(m)$0.00(m)
2019-09-30(m)$4.66M(m)$68.25M$24.87M(m)(m)(m)
2018-09-30$9.68M$9.68M(m)$56.09M$18.09M$74.19M$237.00K(m)
2017-09-30$10.52M$10.52M(m)$53.96M$17.35M$71.31M-$278.00K(m)
2016-09-30$15.97M(m)(m)$52.53M$20.25M$72.78M$401.00K(m)

Revenue and expense 12 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31(m)$16.10M$1.69M$140.67M$65.46M(m)$5.63M-$199.00M
2024-12-31(m)$27.12M$1.27M$143.78M$52.66M(m)$2.43M-$239.60M
2023-12-31(m)$15.84M$65.00K$214.86M$74.59M(m)$1.92M-$308.50M
2022-12-31(m)$106.48M$1.25M$197.59M$55.06M(m)-$1.47M-$126.80M
2021-12-31(m)$524.00M$24.98M$143.55M$56.29M(m)$3.22M$329.60M
2020-12-31(m)$37.51M$2.90M$122.40M$42.58M(m)-$16.42M(m)
2019-12-31(m)$7.28M$1.65M$94.74M$33.54M(m)(m)(m)
2018-12-31(m)$11.28M$1.20M$74.81M$25.30M$100.11M$231.00K(m)
2017-12-31$13.11M$13.11M$817.00K$72.17M$24.64M$96.81M-$199.00K(m)
2016-12-31$25.10M$25.10M$1.35M$72.51M$26.00M$98.51M$1.15M(m)
2015-12-31$10.58M(m)(m)$59.13M$23.38M$82.51M-$1.18M(m)
2014-12-31$6.14M(m)(m)$43.77M$17.07M$60.84M-$535.00K(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Immunome Inc. (IMNM)United States$2.538B-9.45
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Zai Lab Ltd (ZLAB)$2.241B-113.34